1. Academic Validation
  2. 2-Trifluoromethylthiazole-5-carboxamides: Analogues of a Stilbene-Based Anti-HIV Agent that Impact HIV mRNA Processing

2-Trifluoromethylthiazole-5-carboxamides: Analogues of a Stilbene-Based Anti-HIV Agent that Impact HIV mRNA Processing

  • ACS Med Chem Lett. 2021 Oct 29;12(11):1818-1823. doi: 10.1021/acsmedchemlett.1c00428.
Maryam Zamiri 1 Peter K Cheung 2 3 Mark A Brockman 2 3 Zabrina L Brumme 2 3 Benoit Chabot 4 Alan Cochrane 5 David S Grierson 1
Affiliations

Affiliations

  • 1 Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.
  • 2 BC Centre for Excellence in HIV/AIDS, 608-1081 Burrard Street, Vancouver, BC V6Z 1Y6, Canada.
  • 3 Faculty of Health Sciences, Simon Fraser University, Burnaby, BC V5A 1S6, Canada.
  • 4 Department of Microbiology and Infectious Diseases, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1E 4K8, Canada.
  • 5 Department of Molecular Genetics, University of Toronto, Toronto, ON M5S 1A8, Canada.
Abstract

The observation that stilbene 3 (5350150) blocks HIV replication through its impact on HIV mRNA processing prompted a program to develop non-cytotoxic analogues that maintain its mechanism of action. This initially involved replacement of the central double bond in 3 by an amide function and the quinoline motif by a 2-aminobenzothiazole subunit, as in 12jj (R' = Cl), 12pp (R = NO2), and 12vv (R = CF3). On the basis of the possible CF3 ↔ NO2 bioisostere relationship in 12vv and 12pp, compound 23 was prepared and also found to be active. In the final step, the thiazole compounds 28 (GPS488) (EC50 = 1.66 μM) and 29 (GPS491) (EC50 = 0.47 μM) were prepared and evaluated. Similar activity and cell viability values (therapeutic index (TI = CC50/EC50) values of 50-100) were observed in primary peripheral blood mononuclear cells. Furthermore, they remained active against a panel of HIV mutant strains displaying resistance to individual drugs used in antiretroviral therapy. It was determined that compound 29 suppressed expression of the HIV-1 structural protein Gag and altered HIV-1 RNA accumulation, decreasing the abundance of RNAs encoding the structural proteins while increasing levels of viral RNAs encoding the regulatory proteins, a pattern similar to that seen for compound 3.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-139850
    HIV抑制剂
    HIV